Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Giulia Roda, Bindia Jharap, Narula Neeraj, Jean-Frederic Colombel, Giulia Roda, Bindia Jharap, Narula Neeraj, Jean-Frederic Colombel

Abstract

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response-PNR) or lose response during the treatment (secondary loss of response-LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.

Figures

Figure 1
Figure 1
Management of patients with LOR. CRP, C reactive protein; LOR, loss of response.

References

    1. 1Sherman M, Tsynman DN, Kim A et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014; 15: 174–179.
    1. 2Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012; 6: 143–153.
    1. 3Hanauer SB, Feagan BG, Lichtenstein GR et al. ACCENT I Study group. Maintanance Infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 59: 1541–1549.
    1. 4Sands B, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876–885.
    1. 5Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–659.
    1. 6Ben-Hori S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24–30.
    1. 7Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944–948.
    1. 8Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–366.
    1. 9Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618–627.
    1. 10Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–333.
    1. 11Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–265.
    1. 12Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147: 1296–1307.
    1. 13Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
    1. 14Fausel R, Afzali A. Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015; 11: 63–73.
    1. 15Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760–767.
    1. 16D'Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199–212.
    1. 17Ben-Horin S, Chowers Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987–995.
    1. 18Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease. A systematic review. Am J Gastroenterol 2011; 106: 674–684.
    1. 19Ben-Horin S. Loss of response to anti-tumor necrosis factors: What is the next step? Dig Dis 2014; 32: 384–388.
    1. 20Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: The CHARM trial. Gastroenterology 2007; 132: 52–65.
    1. 21Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistula s in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–1405.
    1. 22Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Annals of gastroenterology 2014; 27: 304–312.
    1. 23Katz L, Taylor RP, Cunningham MR et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026–2033.
    1. 24Rojas JT, Taylor RP, Cunningham MR et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolugus monkeys. J Pharmacol Exp Ther 2005;313:578–585.
    1. 25Paul S, Moreau AC, Del Tedesco E et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1288–1295.
    1. 26Roblin X, Marotte H, Rinaudo M et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80–84.
    1. 27Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40: 620–628.
    1. 28West RL, Zelinkova Z, Wolbink GJ et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122–1126.
    1. 29Billioud V, Laharie D, Filippi J et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011; 17: 152–159.
    1. 30Lopez A, Billioud V, Peyrin-Biroulet C et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013; 19: 1528–1533.
    1. 31Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133–1139.
    1. 32Yanai H, Lichtenstein L, Assa A et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015; 13: 522–530.
    1. 33Roblin X, Rinaudo M, Del Tedesco E et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1250–1256.
    1. 34Ben-Horin S, Yavzori M, Katz L et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41–48.
    1. 35St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451–1459.
    1. 36Cesarini M, Katsanos K, Papamichael K et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014; 46: 135–139.
    1. 37Alten R, van den Bosc F. Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis 2014; 17: 5–18.
    1. 38Casteele N, Gils A, Singh S et al. Antibody Response to Infliximab and its impact on Pharmacokinetics can be transient. Am J of Gastroenterol 2013; 108: 962–971.
    1. 39Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–1239.
    1. 40Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–608.
    1. 41Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542–553.
    1. 42Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444.
    1. 43Ong DE, Kamm MA, Hartono JL et al. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. Gastroenterol Hepatol 2013; 28: 1595–1599.
    1. 44Yarur A, Kubiliun M, Czul F et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118–1124.
    1. 45Cornillie F, Hanauer SB, Diamond RH et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721–1727.
    1. 46Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861–1868.
    1. 47Sokol H, Seksik P, Carrat F et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363–1368.
    1. 48Jones GR, Kennedy NA, Lees CW et al. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance—progress and prospects. Aliment Pharmacol Ther 2014; 39: 1253–1265.
    1. 49Colombel JF, Feagan BG, Sandborn WJ et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349–358.
    1. 50Vande Casteele N, Ann Gils. Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of crohn's disease: avoiding failure while lowering costs? Dig Dis Sci 2015; 60: 2571–2573.
    1. 51Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917–924.
    1. 52Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593–1610.
    1. 53Haridas V, Darnay BG, Natarajan K et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 1998; 160: 3152–3162.
    1. 54Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542–18548.
    1. 55Grell M, Zimmermann G, Gottfried E et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999; 18: 3034–3043.
    1. 56Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793–802.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe